Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 73

1.

Prevalence of hepatitis B surface antigen (HBsAg) positivity and its associated factors in Rwanda.

Makuza JD, Rwema JOT, Ntihabose CK, Dushimiyimana D, Umutesi J, Nisingizwe MP, Serumondo J, Semakula M, Riedel DJ, Nsanzimana S.

BMC Infect Dis. 2019 May 3;19(1):381. doi: 10.1186/s12879-019-4013-4.

2.

Retention in care and virological failure among adult HIV+ patients on second-line ART in Rwanda: a national representative study.

Nsanzimana S, Semakula M, Ndahindwa V, Remera E, Sebuhoro D, Uwizihiwe JP, Ford N, Tanner M, Kanters S, Mills EJ, Bucher HC.

BMC Infect Dis. 2019 Apr 5;19(1):312. doi: 10.1186/s12879-019-3934-2.

3.

Rwanda launches a 5-year national hepatitis C elimination plan: A landmark in sub-Saharan Africa.

Umutesi G, Shumbusho F, Kateera F, Serumondo J, Kabahizi J, Musabeyezu E, Ngwije A, Gupta N, Nsanzimana S.

J Hepatol. 2019 Jun;70(6):1043-1045. doi: 10.1016/j.jhep.2019.03.011. Epub 2019 Apr 1. No abstract available.

PMID:
30948269
4.

Viral load detection and management on first line ART in rural Rwanda.

Ndagijimana Ntwali JD, Decroo T, Ribakare M, Kiromera A, Mugwaneza P, Nsanzimana S, Lynen L.

BMC Infect Dis. 2019 Jan 3;19(1):8. doi: 10.1186/s12879-018-3639-y.

5.

Treatment of chronic hepatitis C virus infection in Rwanda with ledipasvir-sofosbuvir (SHARED): a single-arm trial.

Gupta N, Mbituyumuremyi A, Kabahizi J, Ntaganda F, Muvunyi CM, Shumbusho F, Musabeyezu E, Mukabatsinda C, Ntirenganya C, Van Nuil JI, Kateera F, Camus G, Damascene MJ, Nsanzimana S, Mukherjee J, Grant PM.

Lancet Gastroenterol Hepatol. 2019 Feb;4(2):119-126. doi: 10.1016/S2468-1253(18)30382-0. Epub 2018 Dec 11.

PMID:
30552056
6.

Better Outcomes Among HIV-Infected Rwandan Children 18-60 Months of Age After the Implementation of "Treat All".

Arpadi S, Lamb M, Nzeyimana IN, Vandebriel G, Anyalechi G, Wong M, Smith R, Rivadeneira ED, Kayirangwa E, Malamba SS, Musoni C, Koumans EH, Braaten M, Nsanzimana S.

J Acquir Immune Defic Syndr. 2019 Mar 1;80(3):e74-e83. doi: 10.1097/QAI.0000000000001907.

7.

Impact of maternal ART on mother-to-child transmission (MTCT) of HIV at six weeks postpartum in Rwanda.

Mugwaneza P, Lyambabaje A, Umubyeyi A, Humuza J, Tsague L, Mwanyumba F, Mutabazi V, Nsanzimana S, Ribakare M, Irakoze A, Mutaganzwa E, Lombard C, Jackson D.

BMC Public Health. 2018 Nov 12;18(1):1248. doi: 10.1186/s12889-018-6154-6.

8.

Influence of supply-side factors on voluntary medical male circumcision costs in Kenya, Rwanda, South Africa, and Zambia.

Bautista-Arredondo S, Sosa-Rubi SG, Opuni M, Contreras-Loya D, La Hera-Fuentes G, Kwan A, Chaumont C, Chompolola A, Condo J, Dzekedzeke K, Galarraga O, Martinson N, Masiye F, Nsanzimana S, Wamai R, Wang'ombe J; ORPHEA study team.

PLoS One. 2018 Sep 13;13(9):e0203121. doi: 10.1371/journal.pone.0203121. eCollection 2018.

9.

Many pathways to ending AIDS by 2030.

Nsanzimana S, Forrest JI.

Lancet HIV. 2018 Aug;5(8):e407-e408. doi: 10.1016/S2352-3018(18)30131-0. Epub 2018 Jul 17. No abstract available.

PMID:
30021701
10.

Viral Suppression in a Nationwide Sample of HIV-Infected Children on Antiretroviral Therapy in Rwanda.

Nsanzimana S, McArdle F, Remera E, Mulindabigwi A, Ribakare M, Ndimubanzi P, Kayirangwa E, Baribwira C, Riedel DJ, Ntaganira J.

Pediatr Infect Dis J. 2019 Feb;38(2):149-151. doi: 10.1097/INF.0000000000002101.

PMID:
29794653
11.

Patient-level outcomes and virologic suppression rates in HIV-infected patients receiving antiretroviral therapy in Rwanda.

Riedel DJ, Stafford KA, Memiah P, Coker M, Baribwira C, Sebeza J, Karorero E, Nsanzimana S, Morales F, Redfield RR.

Int J STD AIDS. 2018 Aug;29(9):861-872. doi: 10.1177/0956462418761695. Epub 2018 Apr 5.

PMID:
29621951
12.

The role of community health workers and local leaders in reducing attrition among participant in the AIDS indicator survey and HIV incidence in a national cohort study in Rwanda.

Mutagoma M, Sebuhoro D, Nyemazi JP, Mills EJ, Forrest JI, Remera E, Murindabigwi A, Semakula M, Nsanzimana S.

BMC Public Health. 2018 Mar 9;18(1):338. doi: 10.1186/s12889-018-5243-x.

13.

Controlling hepatitis C in Rwanda: a framework for a national response.

Mbituyumuremyi A, Van Nuil JI, Umuhire J, Mugabo J, Mwumvaneza M, Makuza JD, Umutesi J, Nsanzimana S, Gupta N.

Bull World Health Organ. 2018 Jan 1;96(1):51-58. doi: 10.2471/BLT.16.183772. Epub 2017 Nov 27.

14.

Benefits and risks of rapid initiation of antiretroviral therapy.

Ford N, Migone C, Calmy A, Kerschberger B, Kanters S, Nsanzimana S, Mills EJ, Meintjes G, Vitoria M, Doherty M, Shubber Z.

AIDS. 2018 Jan 2;32(1):17-23. doi: 10.1097/QAD.0000000000001671.

15.

Hepatitis B virus and HIV co-infection among pregnant women in Rwanda.

Mutagoma M, Balisanga H, Malamba SS, Sebuhoro D, Remera E, Riedel DJ, Kanters S, Nsanzimana S.

BMC Infect Dis. 2017 Sep 11;17(1):618. doi: 10.1186/s12879-017-2714-0.

16.

Household survey of HIV incidence in Rwanda: a national observational cohort study.

Nsanzimana S, Remera E, Kanters S, Mulindabigwi A, Suthar AB, Uwizihiwe JP, Mwumvaneza M, Mills EJ, Bucher HC.

Lancet HIV. 2017 Oct;4(10):e457-e464. doi: 10.1016/S2352-3018(17)30124-8. Epub 2017 Aug 8.

PMID:
28801191
17.

Comparative efficacy and safety of second-line antiretroviral therapy for treatment of HIV/AIDS: a systematic review and network meta-analysis.

Kanters S, Socias ME, Paton NI, Vitoria M, Doherty M, Ayers D, Popoff E, Chan K, Cooper DA, Wiens MO, Calmy A, Ford N, Nsanzimana S, Mills EJ.

Lancet HIV. 2017 Oct;4(10):e433-e441. doi: 10.1016/S2352-3018(17)30109-1. Epub 2017 Aug 4. Review.

PMID:
28784426
18.

Phased implementation of spaced clinic visits for stable HIV-positive patients in Rwanda to support Treat All.

Nsanzimana S, Remera E, Ribakare M, Burns T, Dludlu S, Mills EJ, Condo J, Bucher HC, Ford N.

J Int AIDS Soc. 2017 Jul 21;20(Suppl 4):21635. doi: 10.7448/IAS.20.5.21635.

19.

Prevalence of hepatitis B and C infection in persons living with HIV enrolled in care in Rwanda.

Umutesi J, Simmons B, Makuza JD, Dushimiyimana D, Mbituyumuremyi A, Uwimana JM, Ford N, Mills EJ, Nsanzimana S.

BMC Infect Dis. 2017 May 2;17(1):315. doi: 10.1186/s12879-017-2422-9.

20.

Writing skills enhancement for public health professionals in Rwanda.

Deonandan R, Sangwa N, Kanters S, Nsanzimana S.

Adv Med Educ Pract. 2017 Mar 31;8:253-256. doi: 10.2147/AMEP.S128403. eCollection 2017.

21.

Mutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing First-Line Regimen: An International Collaboration.

Rhee SY, Varghese V, Holmes SP, Van Zyl GU, Steegen K, Boyd MA, Cooper DA, Nsanzimana S, Saravanan S, Charpentier C, de Oliveira T, Etiebet MA, Garcia F, Goedhals D, Gomes P, Günthard HF, Hamers RL, Hoffmann CJ, Hunt G, Jiamsakul A, Kaleebu P, Kanki P, Kantor R, Kerschberger B, Marconi VC, D'amour Ndahimana J, Ndembi N, Ngo-Giang-Huong N, Rokx C, Santoro MM, Schapiro JM, Schmidt D, Seu L, Sigaloff KCE, Sirivichayakul S, Skhosana L, Sunpath H, Tang M, Yang C, Carmona S, Gupta RK, Shafer RW.

EBioMedicine. 2017 Apr;18:225-235. doi: 10.1016/j.ebiom.2017.03.024. Epub 2017 Mar 19.

22.

"Waiting for DAAs": A retrospective chart review of patients with untreated hepatitis C in Rwanda.

Gupta N, Kabahizi J, Mukabatsinda C, Walker TD, Musabeyezu E, Kiromera A, Van Nuil JI, Steiner K, Mukherjee J, Nsanzimana S, Mbituyumuremyi A.

PLoS One. 2017 Mar 21;12(3):e0174148. doi: 10.1371/journal.pone.0174148. eCollection 2017.

23.

Hepatitis C virus and HIV co-infection among pregnant women in Rwanda.

Mutagoma M, Balisanga H, Sebuhoro D, Mbituyumuremyi A, Remera E, Malamba SS, Riedel DJ, Nsanzimana S.

BMC Infect Dis. 2017 Feb 22;17(1):167. doi: 10.1186/s12879-017-2269-0.

24.

High HIV prevalence and associated risk factors among female sex workers in Rwanda.

Mutagoma M, Samuel MS, Kayitesi C, Gasasira AR, Chitou B, Boer K, Hedt-Gauthier B, Gupta N, Ntaganira J, Nsanzimana S.

Int J STD AIDS. 2017 Oct;28(11):1082-1089. doi: 10.1177/0956462416688137. Epub 2017 Jan 12.

25.

Performance-based financing for improving HIV/AIDS service delivery: a systematic review.

Suthar AB, Nagata JM, Nsanzimana S, Bärnighausen T, Negussie EK, Doherty MC.

BMC Health Serv Res. 2017 Jan 4;17(1):6. doi: 10.1186/s12913-016-1962-9. Review.

26.

Mortality along the continuum of HIV care in Rwanda: a model-based analysis.

Bendavid E, Stauffer D, Remera E, Nsanzimana S, Kanters S, Mills EJ.

BMC Infect Dis. 2016 Dec 1;16(1):728.

27.

Patient-Reported Barriers to Adherence to Antiretroviral Therapy: A Systematic Review and Meta-Analysis.

Shubber Z, Mills EJ, Nachega JB, Vreeman R, Freitas M, Bock P, Nsanzimana S, Penazzato M, Appolo T, Doherty M, Ford N.

PLoS Med. 2016 Nov 29;13(11):e1002183. doi: 10.1371/journal.pmed.1002183. eCollection 2016 Nov. Review.

28.

HIV surveillance in Rwanda: readiness assessment to transition from antenatal care-based to prevention of mother-to-child transmission program-based HIV surveillance.

Balisanga H, Mutagoma M, Remera E, Kayitesi C, Kayirangwa E, Dee J, Malamba S, Boer KR, Hedt-Gauthier B, Umugwaneza P, Nsanzimana S.

Int J Infect Dis. 2016 Nov;52:62-67. doi: 10.1016/j.ijid.2016.08.029. Epub 2016 Sep 8.

29.

Accelerating initiation of antiretroviral therapy.

Ford N, Nsanzimana S.

Lancet HIV. 2016 Nov;3(11):e504-e505. doi: 10.1016/S2352-3018(16)30152-7. Epub 2016 Aug 27. No abstract available.

PMID:
27658872
30.

Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis.

Kanters S, Vitoria M, Doherty M, Socias ME, Ford N, Forrest JI, Popoff E, Bansback N, Nsanzimana S, Thorlund K, Mills EJ.

Lancet HIV. 2016 Nov;3(11):e510-e520. doi: 10.1016/S2352-3018(16)30091-1. Epub 2016 Sep 6. Review.

PMID:
27658869
31.

Costs along the service cascades for HIV testing and counselling and prevention of mother-to-child transmission.

Bautista-Arredondo S, Sosa-Rubí SG, Opuni M, Contreras-Loya D, Kwan A, Chaumont C, Chompolola A, Condo J, Galárraga O, Martinson N, Masiye F, Nsanzimana S, Ochoa-Moreno I, Wamai R, Wang'ombe J; ORPHEA study team.

AIDS. 2016 Oct 23;30(16):2495-2504.

32.

Implementation and Operational Research: Evolution of Couples' Voluntary Counseling and Testing for HIV in Rwanda: From Research to Public Health Practice.

Karita E, Nsanzimana S, Ndagije F, Wall KM, Mukamuyango J, Mugwaneza P, Remera E, Raghunathan PL, Bayingana R, Kayitenkore K, Bekan-Homawoo B, Tichacek A, Allen S.

J Acquir Immune Defic Syndr. 2016 Nov 1;73(3):e51-e58.

33.

A Randomized Switch From Nevirapine-Based Antiretroviral Therapy to Single Tablet Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate in Virologically Suppressed Human Immunodeficiency Virus-1-Infected Rwandans.

Collins SE, Grant PM, Uwinkindi F, Talbot A, Seruyange E, Slamowitz D, Mugeni A, Remera E, Niyonsenga SP, Nyirimigabo J, Uwizihiwe JP, Dongier P, Muhayimpundu R, Mazarati JB, Zolopa A, Nsanzimana S.

Open Forum Infect Dis. 2016 Jul 1;3(3):ofw141. eCollection 2016 Sep.

34.

Operating Characteristics of a Tuberculosis Screening Tool for People Living with HIV in Out-Patient HIV Care and Treatment Services, Rwanda.

Turinawe K, Vandebriel G, Lowrance DW, Uwinkindi F, Mutwa P, Boer KR, Mutembayire G, Tugizimana D, Nsanzimana S, Pevzner E, Howard AA, Gasana M.

PLoS One. 2016 Sep 29;11(9):e0163462. doi: 10.1371/journal.pone.0163462. eCollection 2016.

35.

Transitioning to Country Ownership of HIV Programs in Rwanda.

Binagwaho A, Kankindi I, Kayirangwa E, Nyemazi JP, Nsanzimana S, Morales F, Kadende-Kaiser R, Scott KW, Mugisha V, Sahabo R, Baribwira C, Isanhart L, Asiimwe A, El-Sadr WM, Raghunathan PL.

PLoS Med. 2016 Aug 9;13(8):e1002075. doi: 10.1371/journal.pmed.1002075. eCollection 2016 Aug.

36.

Drug resistance mutations after the first 12 months on antiretroviral therapy and determinants of virological failure in Rwanda.

Ndahimana Jd, Riedel DJ, Mwumvaneza M, Sebuhoro D, Uwimbabazi JC, Kubwimana M, Mugabo J, Mulindabigwi A, Kirk C, Kanters S, Forrest JI, Jagodzinski LL, Peel SA, Ribakare M, Redfield RR, Nsanzimana S.

Trop Med Int Health. 2016 Jul;21(7):928-35. doi: 10.1111/tmi.12717. Epub 2016 Jun 13.

37.

The Prevalence of Syphilis Infection and Its Associated Factors in the General Population of Rwanda: A National Household-Based Survey.

Mutagoma M, Remera E, Sebuhoro D, Kanters S, Riedel DJ, Nsanzimana S.

J Sex Transm Dis. 2016;2016:4980417. doi: 10.1155/2016/4980417. Epub 2016 Mar 30.

38.

TRACnet Internet and Short Message Service Technology Improves Time to Antiretroviral Therapy Initiation Among HIV-infected Infants in Rwanda.

Kayumba K, Nsanzimana S, Binagwaho A, Mugwaneza P, Rusine J, Remera E, Koama JB, Ndahindwa V, Johnson P, Riedel DJ, Condo J.

Pediatr Infect Dis J. 2016 Jul;35(7):767-71. doi: 10.1097/INF.0000000000001153.

39.

Validating the Children's Depression Inventory in the context of Rwanda.

Binagwaho A, Fawzi MCS, Agbonyitor M, Nsanzimana S, Karema C, Remera E, Mutabazi V, Shyirambere C, Cyamatare P, Nutt C, Wagner C, Condo J, Misago N, Kayiteshonga Y.

BMC Pediatr. 2016 Feb 22;16:29. doi: 10.1186/s12887-016-0565-2.

40.

Towards test and treat strategy for HIV in sub-Saharan Africa.

Nsanzimana S, Kanters S, Mills E.

BMJ. 2015 Dec 29;351:h6839. doi: 10.1136/bmj.h6839. No abstract available.

PMID:
26714871
41.

Successive introduction of four new vaccines in Rwanda: High coverage and rapid scale up of Rwanda's expanded immunization program from 2009 to 2013.

Gatera M, Bhatt S, Ngabo F, Utamuliza M, Sibomana H, Karema C, Mugeni C, Nutt CT, Nsanzimana S, Wagner CM, Binagwaho A.

Vaccine. 2016 Jun 17;34(29):3420-6. doi: 10.1016/j.vaccine.2015.11.076. Epub 2015 Dec 17.

PMID:
26704259
42.

Ten-year trends of syphilis in sero-surveillance of pregnant women in Rwanda and correlates of syphilis-HIV co-infection.

Mutagoma M, Balisanga H, Remera E, Gupta N, Malamba SS, Riedel DJ, Nsanzimana S.

Int J STD AIDS. 2017 Jan;28(1):45-53. doi: 10.1177/0956462415624058. Epub 2016 Jul 11.

43.

Prevalence and risk factors for cervical cancer and pre-cancerous lesions in Rwanda.

Makuza JD, Nsanzimana S, Muhimpundu MA, Pace LE, Ntaganira J, Riedel DJ.

Pan Afr Med J. 2015 Sep 11;22:26. doi: 10.11604/pamj.2015.22.26.7116. eCollection 2015.

44.

HIV drug resistance mutations among patients failing second-line antiretroviral therapy in Rwanda.

Ndahimana Jd, Riedel DJ, Muhayimpundu R, Nsanzimana S, Niyibizi G, Mutaganzwa E, Mulindabigwi A, Baribwira C, Kiromera A, Jagodzinski LL, Peel SA, Redfield RR.

Antivir Ther. 2016;21(3):253-9. doi: 10.3851/IMP3005. Epub 2015 Nov 12.

PMID:
26562173
45.

Prevalence of transmitted HIV-1 drug resistance among young adults attending HIV counselling and testing clinics in Kigali, Rwanda.

Mutagoma M, Ndahimana Jd, Kayirangwa E, Dahourou AG, Balisanga H, DeVos JR, McAlister D, Yang C, Bertagnolio S, Riedel DJ, Nsanzimana S.

Antivir Ther. 2016;21(3):247-51. doi: 10.3851/IMP2999. Epub 2015 Oct 12.

PMID:
26458150
46.

Churning in and out of HIV care.

Nsanzimana S, Binagwaho A, Kanters S, Mills EJ.

Lancet HIV. 2014 Nov;1(2):e58-9. doi: 10.1016/S2352-3018(14)70028-1. Epub 2014 Oct 26. No abstract available.

PMID:
26423988
47.

Causes of hospital admission among people living with HIV worldwide: a systematic review and meta-analysis.

Ford N, Shubber Z, Meintjes G, Grinsztejn B, Eholie S, Mills EJ, Davies MA, Vitoria M, Penazzato M, Nsanzimana S, Frigati L, O'Brien D, Ellman T, Ajose O, Calmy A, Doherty M.

Lancet HIV. 2015 Oct;2(10):e438-44. doi: 10.1016/S2352-3018(15)00137-X. Epub 2015 Aug 11. Review.

PMID:
26423651
48.

Effect of baseline CD4 cell count at linkage to HIV care and at initiation of antiretroviral therapy on mortality in HIV-positive adult patients in Rwanda: a nationwide cohort study.

Nsanzimana S, Remera E, Kanters S, Forrest JI, Ford N, Condo J, Binagwaho A, Bucher H, Thorlund K, Vitoria M, Mills EJ.

Lancet HIV. 2015 Sep;2(9):e376-84. doi: 10.1016/S2352-3018(15)00112-5. Epub 2015 Aug 4. Erratum in: Lancet HIV. 2015 Sep;2(9):e364.

PMID:
26423551
49.

HIV care continuum in Rwanda: a cross-sectional analysis of the national programme.

Nsanzimana S, Kanters S, Remera E, Forrest JI, Binagwaho A, Condo J, Mills EJ.

Lancet HIV. 2015 May;2(5):e208-15. doi: 10.1016/S2352-3018(15)00024-7. Epub 2015 Mar 27.

PMID:
26423003
50.

Improving health outcomes through concurrent HIV program scale-up and health system development in Rwanda: 20 years of experience.

Nsanzimana S, Prabhu K, McDermott H, Karita E, Forrest JI, Drobac P, Farmer P, Mills EJ, Binagwaho A.

BMC Med. 2015 Sep 9;13:216. doi: 10.1186/s12916-015-0443-z. Review.

Supplemental Content

Loading ...
Support Center